FLT3 and acute myeloid leukemia: In addition to the four children mentioned above, 1–2 secondary aberrations (WT1m, FLT3-ITD) were used as additional MRD targets in another six children with genetically classified AML and quantified in parallel with the primary aberrations (Supplementary Fig. 3).